Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

BioVaxys Technology Corp. BVAXF

Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by Humaniston Aug 02, 2022 9:29pm

143 Views

Post# 34867143

BIOV SETTLES $517,854 DEBT BY ISSUING SHARES AT $0.10 A SHAR

Which is approximately 5,178,500 shares
 	
 	BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT
 		by @newswire on 2 Aug 2022, 19:01
 		     

VANCOUVER, B.C., Aug. 2, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") further to its news release dated July 4, 2022, BioVaxys announces that it has settled an aggregate of $517,854 in debt through the issuance of common shares issued at a deemed price of $0.10 per common share.

https://ceo.ca/@newswire/biovaxys-announces-completed-debt-settlement